Stocktoria
MYRIAD GENETICS INC MYGN
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1995-10-06
MYRIAD GENETICS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 69.9% | 69.9% | 68.6% | 70.2% | — |
| Operating margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| Net margin | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% |
| Return on assets | -51.8% | -12.4% | -23.0% | -9.3% | -2.1% |
| Return on equity | -99.4% | -18.2% | -33.6% | -12.6% | -2.8% |
| Debt / equity | 0.33× | 0.06× | 0.05× | 0.00× | 0.00× |
| Current ratio | 2.49 | 1.82 | 2.01 | 2.00 | 2.37 |
| Revenue growth | -1.6% | 11.2% | 11.0% | -1.8% | 24.0% |
Source: SEC EDGAR filings · CIK 0000899923 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.